9 unchanged sentences
District Court for the Northern District of Illinois.
+Added: In May 2025, the U.S.
+Added: District Court for the Northern District of Illinois granted summary judgment in favor of Abbott on all claims in the first "bellwether" case and entered judgment for Abbott.
+Added: The plaintiff has filed an appeal.
+Added: District Court for the Northern District of Illinois granted summary judgment in favor of Abbott in each of the second and third "bellwether" cases in August and October 2025, respectively.
In addition, in December 2021, a purported class of Canadian preterm infants filed suit in British Columbia that makes similar allegations as those made in the United States against Abbott.
2 unchanged sentences
In a trial held in July 2024, a jury in a Missouri state court awarded a plaintiff $495 million in damages.
−Removed: Abbott stands by its products and the information it provided about them, and it appealed this jury’s verdict with the Missouri Court of Appeals in December 2024.
+Added: Abbott stands by its products and the information it provided about them, and it appealed this jury’s verdict to the Missouri Court of Appeals in December 2024.
In a trial held in October 2024 involving Abbott and another infant formula manufacturer and the treating hospital as co-defendants, a jury in a Missouri state court returned a unanimous verdict for Abbott and its co-defendants.
In December 2024, the plaintiff filed a motion for a new trial.
−Removed: As previously disclosed, DexCom, Inc.
−Removed: (Dexcom) and Abbott filed various patent infringement actions against each other over certain of the other company’s continuous glucose monitoring products in the U.S., Germany, the U.K, Spain, and the Unified Patent Court, which litigation commenced in 2021.
−Removed: In December 2024, Abbott reached an agreement with Dexcom to settle all outstanding patent disputes between the companies in cases related to continuous glucose monitoring products.
−Removed: The agreement will result in the dismissal of all pending cases in courts and patent offices worldwide.
−Removed: In November 2022, Abbott learned that the United States Department of Justice, through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of infant formula.
−Removed: In December 2022, Abbott received a subpoena from the Enforcement Division of the Commission requesting information relating to Abbott’s powder infant formula business and related public disclosures.
+Added: In March 2025, the Missouri state court granted the plaintiff's motion for a new trial, and Abbott appealed the ruling to the Missouri Court of Appeals.
+Added: In November 2022, Abbott learned that the United States Department of Justice (DOJ), through the United States Attorney’s Office for the Western District of Michigan, is conducting a criminal investigation related to Abbott’s manufacturing of powdered infant formula.
In January 2023, Abbott received a civil investigative demand from the United States Federal Trade Commission seeking information in connection with its investigation of companies who participate in bids for WIC infant formula contracts.
−Removed: In addition, multiple civil lawsuits have been filed against Abbott relating to Abbott’s manufacturing of certain powder infant formula products.
+Added: In addition, multiple civil lawsuits have been filed against Abbott relating to Abbott’s manufacturing of certain powdered infant formula products.
Six shareholder derivative lawsuits against certain of Abbott’s current and former directors and officers are pending in a consolidated proceeding, In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation , in the U.S.
12 unchanged sentences
In February 2025, the court granted in part and denied in part the committee's motion, allowing written discovery to proceed.
+Added: In November 2025, the DOJ intervened, in part, in a civil qui tam lawsuit previously filed under seal against Abbott by three private individuals in the U.S.
+Added: District Court for the Western District of Michigan.
+Added: The DOJ’s intervention is related to Abbott’s manufacturing of powdered infant formula products at its facility in Sturgis, Michigan.
+Added: The DOJ alleges certain violations of the Federal False Claims Act and unjust enrichment, and it seeks various damages, including statutory penalties and disgorgement of profits.
+Added: In December 2025, the Attorneys General of several states filed a consolidated complaint-in-intervention in the same lawsuit alleging violations of certain state laws, including false claims acts, and seeking damages and penalties.
MINE SAFETY DISCLOSURES
11 unchanged sentences
2020 to 2021 — President and Chief Executive Officer, and Director.
−Removed: 2018 to 2020 — President and Chief Operating Officer, and Director since 2019.
Elected Corporate Officer — 2008.
−Removed: 2013 to present — Executive Vice President, General Counsel and Secretary.
−Removed: Elected Corporate Officer — 2012.
2024 to present — Executive Vice President, Finance a nd Chief Financial Officer.
1 unchanged sentence
2020 to 2023 — Vice President, Finance a nd Controller.
−Removed: 2017 to 2020 — Divisional Vice President, Controller, Medical Devices.
Elected Corporate Officer — 2020 .
+Added: 2025 to present — Executive Vice President, General Counsel and Secretary.
+Added: 2024 to 2025 — Senior Vice President, Legal .
+Added: 2023 to 2024 — Vice President, Specialty Legal .
+Added: 2021 to 2023 — Divisional Vice President and Associate General Counsel, Legal Regulatory and Compliance.
+Added: Elected Corporate Officer — 2023.
Earnhardt, 56
12 unchanged sentences
Elected Corporate Officer — 2014.
−Removed: Andrea Wainer, 56
−Removed: 2019 to present — Executive Vice President, Rapid and Molecular Diagnostics.
+Added: Christopher J.
+Added: 2025 to present — Executive Vice President, Diabetes Care.
+Added: 2023 to 2024 — Senior Vice President, Commercial Operations and Marketing, Abbott Diabetes Care .
+Added: 2021 to 2023 — Vice President, Commercial Operations and Marketing, Abbott Diabetes Care .
+Added: 2019 to 2021 — Senior Vice President, Rapid Diagnostics.
Elected Corporate Officer — 2015.
+Added: Eric Shroff, 54
+Added: 2025 to present — Senior Vice President, Rapid and Molecular Diagnostics.
+Added: 2018 to 2025 — Vice President, Abbott Point of Care.
+Added: Elected Corporate Officer — 2018.
McCoy, Jr., 56
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.